Smurfit WestRock plc Ordinary Shares vs BIO-TECHNE Corp — how do they compare? Smurfit WestRock plc Ordinary Shares trades at $41.29 (market cap $21.74B), while BIO-TECHNE Corp trades at $72.44 (market cap $11.36B). The key difference: Smurfit WestRock plc Ordinary Shares is the larger of the two by market cap, and Smurfit WestRock plc Ordinary Shares pays the higher dividend (4.36%). Which is the better fit depends on your goals — on Pluang, investors hold Smurfit WestRock plc Ordinary Shares for 0 Days and BIO-TECHNE Corp for 64 Days on average.
| SW | TECH | |
|---|---|---|
Market Cap | $21.74B | $11.36B |
Volume | 5,178,763 | 5,390,331 |
Sector | Consumer Cyclical | Health |
52-Week High | $51.84 | $72.61 |
52-Week Low | $32.79 | $43.31 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $35.23B | $11.39B |
Dividend Yield | 4.36% | 0.44% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Bio-Techne (TECH) trades at $72.45, down 0.11% on the day, near its 52-week high of $72.70. The stock shows bullish technical signals with strong moving average support. Fundamentally, the company maintains solid gross margins of 65.77% but faces declining net income margins, dropping from 24.6% in 2022 to 6.01% in 2025. Recent shareholder approval of Merck KGaA's acquisition at $73 per share provides a clear near-term catalyst.
The pending acquisition offers limited upside from current levels but provides downside protection. However, declining profitability trends and elevated valuation ratios (P/E 62.46) pose risks if the deal falls through. Investors should weigh the acquisition premium against fundamental deterioration in earnings quality.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Smurfit WestRock plc is an Ireland-headquartered packaging company that manufactures corrugated containers and consumer packaging from containerboard and paperboard, operating mills, converting plants, and recycling facilities across more than 40 countries.
Read more on SW →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →